Untitled

Abstract

Olmesartan medoxomil, a BCS class II drug, is an angiotensin-II receptor antagonist used for the treatment of hypertension. A liquisolid tablet of Olmesartan medoxomil was developed to improve its dissolution and flow properties. The commonly used carrier Avicel was compared with Neusilin. Because of higher liquid load factor, Neusilin was selected as a carrier for further optimization study using 3 2 Factorial design. Two independent factors, % drug concentration in a liquid vehicle (X1) and carrier coating ratio (X2) were studied, each with three levels and the systems was assessed for two dependent variables; % drug dissolution and angle of repose. Mathematical equations and response surface plots were used to relate the dependent and independent variables. All prepared liquisolid formulations were characterized for pre-and post-compression parameters. The optimized formulation F7 (15% drug concentration and 30 carrier coating ratio) was tested for X-ray powder diffractometry and FTIR. Results showed that maximum drug dissolution was exhibited by systems with minimum drug concentration in liquid vehicle and optimum carrier to coating ratio. Optimized formulation displayed significantly enhanced dissolution profiles than that of marketed formulation. In conclusion, avicel could be replaced by neusilin for the formulation of low weight liquisolid tablets along with increased dissolution.